Premium
Angiographic and clinical one‐year follow‐up of the Cordis tantalum coil stent in a multicenter international study demonstrating improved restenosis rates when compared to pooled PTCA and BENESTENT‐I data: The European Antiplatelet Stent Investigation (EASI)
Author(s) -
Rothman Martin T.,
Serruys Patrick W.,
Grollier Gilles,
Hoorntje Jan C.A.,
van den Bos Arjan A.,
Wijns William,
Gershlick Anthony H.,
Van Es GerritAnne,
Melkert Rein,
Eijgelshoven Marcel H.J.,
Lenderink Timo T.,
Richardson Gail,
DilleAmo Carlie
Publication year - 2001
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/1522-726x(200102)52:2<249::aid-ccd1060>3.0.co;2-t
Subject(s) - medicine , mace , restenosis , stent , cardiology , conventional pci , thrombosis , surgery , radiology , myocardial infarction
The Cordis tantalum coil stent was assessed in a nonrandomized multicenter trial: 275 patients with stable or unstable angina were entered. Clinical follow‐up was for 1 year, with repeat angiography at 6 months. The major adverse cardiac event rates (MACE) were 3%, 14%, and 17% at 1, 7, and 13 months, respectively. The procedural success rate was 96% and the subacute occlusion rate 1.5%, in a group of patients over 60% of whom had ACC/AHA type B2 or C lesions. The binary restenosis rate at 6 months was 17.3%. Minimum lumen diameter increased from 1.07 ± 0.28 mm preprocedure to 2.93 ± 0.34 mm poststenting and at 6 months was 1.99 ± 0.69 mm. These results demonstrate that the Cordis tantalum stent can be used to treat complex lesions with good procedural success and low rates of subacute thrombosis and restenosis at 6 months. Cathet Cardiovasc Intervent 2001;52:249–259. © 2001 Wiley‐Liss, Inc.